Former Merck and NASA Leaders Join SpaceMD to Accelerate Space-Based Pharmaceutical R&D
核心洞察
Redwire's SpaceMD (搜索) appoints former Merck (搜索) Principal Investigator Paul Reichert and former NASA Director Niki Werkheiser to strategic advisory roles to advance space-enabled drug development.
Reichert, who contributed to early formulation and crystallization research of pembrolizumab (Keytruda), will identify promising drug candidates and support an orbital research and manufacturing pipeline.
Werkheiser, who oversaw more than $1.5 billion in technology investments at NASA, will develop new therapeutic concepts and expand pharmaceutical research on the ISS and emerging commercial platforms.
Redwire Corporation (搜索) (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced the appointment of two pioneering industry leaders to strategic advisory roles at Space Microgravity Development LLC (SpaceMD (搜索)), its venture company focused on leveraging the microgravity environment to create innovations in biotech and other fields. Paul Reichert, former Principal Investigator at Merck (搜索) Research Laboratories, and Niki Werkheiser, former Director of Technology Maturation at NASA's Space Technology Mission Directorate, will expand SpaceMD's leadership in space-enabled research and pharmaceutical innovation.
"SpaceMD (搜索)'s mission is to unlock new pharmaceutical drugs through cutting-edge, space-based research. Bringing Paul and Niki onto our advisory team significantly advances that mission," said John Vellinger, CEO of SpaceMD. "Their unparalleled expertise in drug development and go-to-market strategy, biopharmaceutical research, and space technology will bolster the momentum already underway as SpaceMD continues to lead the industry in in‑space pharmaceutical research."
Scientific Leadership from Merck's Pipeline
As Scientific Advisor, Reichert will shape SpaceMD (搜索)'s scientific and commercial roadmap by identifying promising drug candidates and supporting the development of an orbital research and manufacturing pipeline. During his tenure at Merck (搜索), Reichert played a key role in advancing the company's research pipeline, notably contributing to the early formulation and crystallization research of pembrolizumab—the active ingredient in Keytruda, a breakthrough immunotherapy used to treat multiple cancers. His work at Merck and Schering-Plough has helped shape the pharmaceutical industry's understanding of molecular behavior, formulation challenges, and drug development pathways.
NASA Expertise for Space-Based Therapeutics
In her role as Strategic Advisor, Werkheiser will work closely with the SpaceMD (搜索) team and biotech partners to develop new therapeutic concepts and establish new opportunities to apply SpaceMD technologies to pharmaceutical research on the International Space Station (ISS) and emerging commercial platforms. Werkheiser advises across the commercial space ecosystem, drawing from three decades of experience successfully leading space programs and partnerships from concept to operations on space shuttles, the ISS, and the lunar surface. Most recently, she served as NASA's director of technology maturation, where she oversaw more than $1.5 billion in technology investments across industry and government. Previously, she established NASA's In-Space Manufacturing Initiative as a foundational capability for long-duration missions.
Growing Momentum in Space Pharma
The appointments come amid rising interest in space-enabled pharmaceutical research, as SpaceMD (搜索) accelerates work with a growing number of pharmaceutical customers and partners. The venture company is focused on unlocking new pharmaceutical drugs through space-based research, capitalizing on the unique properties of microgravity to drive innovations that are difficult or impossible to achieve under terrestrial conditions.